Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days
The recent 10-day sales pace would correspond to approximately $21.9 million annually if sustained for a full year.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cosmos Health (COSM) reported record United States direct-to-consumer sales of more than $92,000 in a single day on October 11, 2026. Sales over the trailing 30 days totaled $902,000, or approximately $30,000 per day. Average daily sales over the past 10 days exceeded $60,000, double the 30-day average.
The figures cover the company's own branded United States online stores, including 18 Series nutraceuticals, NOOR and skincare products, through individual purchases and subscriptions. Sustained for a full year, the 10-day rate would correspond to approximately $21.9 million in annualized sales; this is not a completed year's result. Cosmos Health projects annual revenue of over $23 million for its United States products within the next 12 to 18 months and is evaluating extending the direct-to-consumer model to additional portfolio brands and markets.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointTrailing 30-day sales totaled $902,000, or approximately $30,000 per day.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Past 10-day average daily sales exceeded $60,000, double the 30-day average; sustained annually, approximately $21.9 million.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Cosmos Health projects United States product annual revenue of over $23 million within the next 12 to 18 months.
- Minor pointUnited States direct-to-consumer sales reached a single-day record of more than $92,000 on October 11, 2026.
- Minor pointCosmos Health is evaluating expansion of its direct-to-consumer model to additional portfolio brands and markets.
Negative
- None.
Details
Market move: COSM +11.01% vs previous close. U.S. DTC sales record
On Oct 13, the day this news came out, the latest delayed price for COSM is 11.01% above the previous close. Our momentum scanner has recorded 38 alerts for this stock so far that day. The latest delayed price is $0.39.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Record single-day U.S. sales
- More than $92,000
- October 11, 2026
- 30-day U.S. sales
- $902,000
- Trailing 30 days
- 10-day average daily sales
- More than $60,000
- Past 10 days; double the 30-day average
- Projected U.S. product revenue
- Over $23 million
- Company projection for the next 12 to 18 months, previously reported
Key Terms
good manufacturing practices (gmp) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, IL / ACCESS Newswire / October 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its United States direct-to-consumer sales reached a record of more than
United States Direct-to-Consumer Sales
The figures cover sales through the Company's own branded online stores in the United States, including the 18 Series nutraceuticals, the NOOR brand and skincare products, sold both as individual purchases and through subscriptions.
Over the trailing 30 days, sales totaled
As previously reported, the Company has projected annual revenue of over
A Direct Relationship with the Consumer
The Company believes that selling directly to consumers carries attractive margins and provides a direct relationship with the end customer, together with visibility over purchasing behavior that can inform product development and marketing across the wider portfolio. The channel also gives the Company greater control over pricing, presentation and the customer experience.
The United States has been the starting point for this model. Cosmos Health is evaluating opportunities to extend it over time, both to additional brands within its portfolio and to further markets.
Greg Siokas, CEO of Cosmos Health, stated: "Our United States business is accelerating. We did
"We are reaching consumers directly, learning what they buy and what brings them back. At the current pace, we are already approaching the over
"The United States is proving to be a strong testing ground. What we learn here, which products convert, how customers behave and what drives repeat purchases, should apply to other brands we bring onto the platform, and we are evaluating how best to extend it to other brands in our portfolio and to further markets."
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; the timing, execution, regulatory clearance, valuation, structuring, and completion of any potential asset-backed or tokenized financing program; the legal, regulatory, and technological risks associated with digital assets and blockchain-based financial structures; the conversion of contract manufacturing pipeline volumes into production and revenue, including the timing, volume and terms of orders placed under multi-year agreements; the realization of anticipated gross margins; the timing, cost and completion of planned capital investments; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was Cosmos Health's record daily United States direct-to-consumer sales figure?
Cosmos Health's United States direct-to-consumer sales reached more than $92,000 on October 11, 2026, a single-day record. The figures cover sales through its own branded online stores, including individual purchases and subscriptions.
How much did Cosmos Health sell through its United States direct-to-consumer channel over the past 30 days?
Cosmos Health recorded $902,000 in United States direct-to-consumer sales over the trailing 30 days, approximately $30,000 per day. Average daily sales over the past 10 days exceeded $60,000, double the 30-day average.